New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging
Improving the efficacy of engineered T-cells – from gene transfer to genome editing
A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies
Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
Next-generation sequencing can identify molecular alterations in glioma: are we ready for targeted treatments?
Three studies support the use of NGS to better understand the molecular drivers of this brain tumour, but effective targeted treatments are still lacking
Building a lasting foundation for precision oncology
While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients.
What is the state of play for molecular profiling in gynaecological malignancies?
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
Is molecular profiling for gynaecological cancers worth the cost?
In this era of precision medicine, affordable profiling is essential
Is molecular profiling useful in the management of breast cancer?
The value of genomic testing is being increasingly demonstrated and will evolve over time
Encouraging results with savolitinib in NSCLC with MET exon14 skipping mutations
Overall survival data are in line with those from other MET tyrosine kinase inhibitors and show promise in a tumour subtype with poor prognosis
How can we continue to improve outcomes for our patients with lung cancer?
Advances made in the treatment of advanced lung cancer are now being introduced at earlier stages of disease